Trial Profile

A Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NRTX-1001 (Primary)
Indications Partial epilepsies; Seizures; Temporal-lobe-epilepsy
Focus Adverse reactions; First in man
Acronyms EPIC
Sponsors Neurona Therapeutics

Most Recent Events

08 Dec 2025 According to a Neurona Therapeutics media release, data from the trail were presented at the Annual Meeting of the American Epilepsy Society (AES), taking place December 5-9, 2025, in Atlanta, Georgia.
08 Dec 2025 Results presented in the Neurona Therapeutics Media Release
28 Nov 2025 Planned number of patients changed from 58 to 88.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com